Xiamen Innovax Biotech Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private, Subsidiary
- Established
- 2005-03-28
- Employees
- -
- Market Cap
- -
- Website
- http://www.innovax.cn
Clinical Trials
10
Active:0
Completed:9
Trial Phases
1 Phases
Phase 4:9
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (9 trials with phase data)• Click on a phase to view related trials
Phase 4
9 (100.0%)A Post-marketing Observational Database Study Monitoring the Safety of CecolinⓇ
Completed
- Conditions
- Autoimmune DiseasesAdverse Pregnancy Outcomes
- First Posted Date
- 2025-02-13
- Last Posted Date
- 2025-02-13
- Lead Sponsor
- Xiamen Innovax Biotech Co., Ltd
- Target Recruit Count
- 1322084
- Registration Number
- NCT06824896
- Locations
- 🇨🇳
Xiamen Innovax Biotech Co., Ltd, Xiamen, Fujian, China
Safety and Immunogenicity Study of Thiomersal-free Hepatitis E Vaccine in People Ages 16 Years and Above
Phase 4
Completed
- Conditions
- Hepatitis E
- First Posted Date
- 2024-08-21
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Xiamen Innovax Biotech Co., Ltd
- Target Recruit Count
- 612
- Registration Number
- NCT06564116
- Locations
- 🇨🇳
Youxi County Center for Disease Control and Prevention, Sanming, Fujian, China
Immunogenicity and Safety of One Dose of HPV Vaccine
Phase 4
Completed
- Conditions
- Human Papillomavirus Vaccines
- First Posted Date
- 2024-04-03
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- Xiamen Innovax Biotech Co., Ltd
- Target Recruit Count
- 200
- Registration Number
- NCT06345885
- Locations
- 🇨🇳
Fujian Provincial Center for Disease Control and Prevention, Fuzhou, Fujian, China
Lot Consistency Clinical Trial of of Recombinant HPV Bivalent Vaccine in 9 to14 Years Old Healthy Female
Phase 4
Completed
- Conditions
- Cervical Intraepithelial NeoplasiaVaginal Intraepithelial NeoplasiaCervical CancerVulvar Intraepithelial NeoplasiaPersistent Infection
- First Posted Date
- 2022-06-21
- Last Posted Date
- 2022-06-29
- Lead Sponsor
- Xiamen Innovax Biotech Co., Ltd
- Target Recruit Count
- 540
- Registration Number
- NCT05426148
- Locations
- 🇨🇳
Dongtai City Center for Disease Control and Prevention Dongtai, Jiangsu, Dongtai, Jiangsu, China
Immunogenicity and Safety of Co-immunization With Cecolin and Hecolin
Phase 4
- Conditions
- Human Papilloma Virus Infection Type 16Human Papilloma Virus Infection Type 18Hepatitis E Virus Infection
- First Posted Date
- 2022-06-13
- Last Posted Date
- 2022-06-13
- Lead Sponsor
- Xiamen Innovax Biotech Co., Ltd
- Target Recruit Count
- 480
- Registration Number
- NCT05415345
- Locations
- 🇨🇳
Zhejiang Provincial Center for Disease Control and Prevention, Hanzhou, Zhejiang, China
- Prev
- 1
- 2
- Next
News
No news found